Search results
Results From The WOW.Com Content Network
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows. The Administrative Controlled Substances Code Number and Federal Register citation for each substance is included.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Rosuvastatin was patented in 1991 and approved for medical use in the United States in 2003. [6] [7] It is available as a generic medication. [6] In 2022, it was the thirteenth most commonly prescribed medication in the United States, with more than 37 million prescriptions.
When two drugs affect each other, it is a drug–drug interaction (DDI). The risk of a DDI increases with the number of drugs used. [1] A large share of elderly people regularly use five or more medications or supplements, with a significant risk of side-effects from drug–drug interactions. [2] Drug interactions can be of three kinds:
Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin. [60] HIV-positive people taking protease inhibitors: Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices. [61] Persons taking gemfibrozil, a non-statin lipid-lowering drug Atorvastatin
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. The complete list of Schedule V substances is as follows.